Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gilead Sciences : Kite Partners With Shoreline Biosciences to Develop Cancer Therapies

06/17/2021 | 10:32am EDT


© MT Newswires 2021
All news about GILEAD SCIENCES, INC.
07/21GILEAD SCIENCES : Statement on Positive Phase 3 AMBITION Study Findings for the ..
PU
07/20BIONTECH : to Acquire Kite's Neoantigen TCR Cell Therapy R&D Platform and Manufa..
AQ
07/20ARCUS BIOSCIENCES : Chief Medical Officer Resigns to Join Gilead's Oncology Team
MT
07/20PRESS RELEASE : Japan becomes first country to approve Ronapreve (casirivimab an..
DJ
07/19ADRs End Lower; Toyota, BioNTech Among Companies Actively Trading
DJ
07/19Health Care Down Amid Defensive Bias -- Health Care Roundup
DJ
07/19GILEAD SCIENCES : BioNTech to Buy Gilead Sciences Unit's Cell Therapy R&D Platfo..
MT
07/19GILEAD SCIENCES : New Phase 3 Data Support the Sustained, Long-Acting Efficacy o..
AQ
07/19GILEAD SCIENCES : Four-Year Biktarvy Data Presented at IAS 2021 Demonstrate High..
AQ
07/19BIONTECH : to Buy Neoantigen TCR Cell Therapy Platform, Facility from Gilead's K..
MT
More news
Financials (USD)
Sales 2021 24 674 M - -
Net income 2021 6 917 M - -
Net Debt 2021 21 985 M - -
P/E ratio 2021 13,0x
Yield 2021 4,12%
Capitalization 86 099 M 86 099 M -
EV / Sales 2021 4,38x
EV / Sales 2022 4,33x
Nbr of Employees 13 600
Free-Float 99,9%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | MarketScreener
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 31
Last Close Price 68,65 $
Average target price 75,07 $
Spread / Average Target 9,35%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.17.83%85 134
WUXI APPTEC CO., LTD.37.17%71 226
REGENERON PHARMACEUTICALS21.48%57 013
BIONTECH SE244.68%55 555
VERTEX PHARMACEUTICALS-17.06%50 308
BEIGENE, LTD.24.51%33 627